ZAGREB, 23 Oct (Hina) - Croatia is below the EU average in the use of biosimilar drugs, which are much cheaper and more available than original biologic drugs, a conference heard earlier this week, organised to mark ten years of the use of biosimilars in Croatia's healthcare.
(Hina) ha